OncoSil Medical Ltd
OSL
Company Profile
Business description
OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. It operates in one segment. the device development for new medical treatments. Geographically, the company derives its maximum revenue from Europe and the rest from Australia and New Zealand.
Contact
7 Eden Park Drive
Level 5
Macquarie Park
SydneyNSW2113
AUST: +61 289359629
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
30 June 2025
Employees
2
Stocks News & Analysis
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
stocks
What next for Tesla as 2024 deliveries disappoint?
Tesla shares started the year on a sour note. We think they continue to price in ambitious growth going forward.
stocks
Best and worst performing ASX sectors of 2024
Exploring the ASX sectors that moved the market this year.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,542.90 | 26.40 | 0.31% |
| CAC 40 | 7,426.24 | 19.45 | -0.26% |
| DAX 40 | 20,187.51 | 28.68 | -0.14% |
| Dow JONES (US) | 42,706.56 | 25.57 | -0.06% |
| FTSE 100 | 8,194.62 | 55.04 | -0.67% |
| HKSE | 19,447.58 | 240.71 | -1.22% |
| NASDAQ | 19,864.98 | 243.30 | 1.24% |
| Nikkei 225 | 40,083.30 | 776.25 | 1.97% |
| NZX 50 Index | 13,042.06 | 30.87 | -0.24% |
| S&P 500 | 5,975.38 | 32.91 | 0.55% |
| S&P/ASX 200 | 8,285.10 | 27.70 | 0.34% |
| SSE Composite Index | 3,229.64 | 22.72 | 0.71% |